Chronic myelogenous leukemia - Treatment and monitoring;Chronische Myeloische Leukämie - Therapie und Monitoring

Deutsches Arzteblatt

Volumn 107, Issue 7, 2010, Pages 114-121

  Von Bubnoff, Nikolas ^a   Duyster, Justus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIARRHEA; DRUG MONITORING; HUMAN; LEUKEMIA REMISSION; LIVER DYSFUNCTION; MORTALITY; MUSCLE CRAMP; NEUTROPENIA; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PROGRESSION FREE SURVIVAL; REVIEW; THERAPY RESISTANCE; THROMBOCYTOPENIA;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PREVALENCE; PYRIMIDINES; RISK ASSESSMENT; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77951448482     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2010.0114     Document Type: Review

References (25)

1. Baccarani M, Saglio G, Goldman J, et al.: Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006; 108: 1809-20.
2. Baccarani M, Cortes J, Pane F, et al.: Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009; 27 (35) : 6041-51.
3. Hochhaus A, Brümmendorf T, Le Coutre P: Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen. Chronische Myeloische Leukämie. http://www.dgho. de/onkopedia
4. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. www.nccn.org
5. Hochhaus A, Druker B, Sawyers C, et al.: Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111: 1039-43.
6. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004. (Pubitemid 36302244)
7. Hughes T P, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-32. (Pubitemid 37211057)
8. Hochhaus A, O'Brien SG, Guilhot F, et al.: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-61.
9. Roy L, Guilhot J, Krahnke T, et al.: Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108: 1478-84. (Pubitemid 44316111)
10. de Lavallade H, Apperley J F, Khorashad JS, et al.: Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-63.
11. Druker BJ, Guilhot F, O'Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17. (Pubitemid 44903745)
12. Deininger MW, O'Brien SG, Ford JM, Druker BJ: Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21: 1637-47. (Pubitemid 46594119)
13. Quintas-Cardama A, Cortes JE, Kantarjian H: Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma 2008; 8 Suppl 3: p. 82-8. (Pubitemid 351692305)
14. Hughes T, Deininger M, Hochhaus A, et al.: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37. (Pubitemid 43990609)
15. Goldman JM: How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828-37. (Pubitemid 350006935)
16. Kantarjian H, Schiffer C, Jones D, Cortes J: Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008; 111: 1774-80. (Pubitemid 351451481)
17. Kantarjian H, O'Brien S, Shan J, et al.: Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 2008; 112: 837-45.
18. Marin D, Milojkovic D, Olavarria E, et al.: European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112: 4437-44.
19. Cortes J, Rousselot P, Kim DW, et al.: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207-13.
20. Hochhaus A, Baccarani M, Deininger M, et al.: Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200-6.
21. Apperley J F, Cortes JE, Kim DW, et al.: Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib fail - ure: the START a trial. J Clin Oncol 2009; 27: 3472-9.
22. Cortes J, Kim DW, Raffoux E, et al.: Efficacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22: 2176-83.
23. Kantarjian HM, Giles F, Gattermann N, et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540-6.
24. Shah N P, Kantarjian HM, Kim DW, et al.: Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204-12.
25. le Coutre P, Ottmann OG, Giles F, et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated phase chronic myelogenous leukemia. Blood 2008; 111: 1834-9.